Prevalence of abnormal liver biochemistry and its impact on COVID-19 patients’ outcomes: a single-center Greek study

Cholongitas, Evangelos

doi:10.20524/aog.2022.0709

Cited by 15 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormalities of liver biochemistry in COVID-19 are generally characterized by slight (1-2 times the superior limit of normal) increases in alanin-aminotransferaze (ALT) aspartat-aminotransferaze (AST) levels, reported in approximately 40–60% of pacients. Furthermore, hypoalbuminemia, a nonspecific marker of disease severity, was reported in 36–38% of cases [ 42 ] associated with severe outcomes of COVID-19 [ 43 ]. However, severe liver lesions, increased serum bilirubin levels, and synthetic liver dysfunctions are uncommon in pacients with COVD-19 [ 39 , 40 , 42 ].…”

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

“…Furthermore, hypoalbuminemia, a nonspecific marker of disease severity, was reported in 36–38% of cases [ 42 ] associated with severe outcomes of COVID-19 [ 43 ]. However, severe liver lesions, increased serum bilirubin levels, and synthetic liver dysfunctions are uncommon in pacients with COVD-19 [ 39 , 40 , 42 ]. Regardless of pre-existing liver illness status, liver biochemistry abnormalities are detected at equal rates [ 44 – 46 ].…”

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

“…SARS-CoV-2 is associated with a systemic infection that, like many other infections, is expected to enhance liver biochemistry by producing cytokine [ 54 , 55 ]. Patients with significantly increased serum LT levels frequently have high liver-produced CRP, D-dimers, ferritin, and IL-6 levels [ 42 , 43 , 54 – 56 ].…”

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

“…The main factor causing CRP generation and high levels of IL-6, which are connected to liver damage in COVID-19, is IL-6 generated by T cells, macrophages, and monocytes in response to the activation of the inborn and adaptive immune systems [ 42 , 54 ]. In particular, the level of IL-6 rises during COVID-19 illness, falls as patients recover, and is correlated with the severity of the disease.…”

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

“…There have been contradictory opinions about liver enzymes involvement in mortality and morbidity prediction, as some have discarded the hypothesis that elevation in liver function tests may have any predictive value [ 69 , 73 ], and others proved that elevation over 5 times the upper limit is strongly correlated with high mortality risk [ 39 , 42 , 74 , 75 ]. It was suggested that patients with severe disease might respond more robustly to intensive treatments and prognostic indicators of higher liver enzyme levels [ 76 ].…”

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

See 4 more Smart Citations

Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver

Săbiescu

Kamal

et al. 2022

JMedLife

View full text Add to dashboard Cite

Since COVID-19 was declared a pandemic by the World Health Organization, the scientific community has tried to protect the population from the infection and its effects through multiple lines of evidence. Patients at high risk of developing severe disease were advised to protect themselves and practice effective physical distancing. Phenotypes specific to this infection need to be reviewed to understand COVID-19 and its clinical manifestations. When the pandemic began, the scientific community was concerned with the unfavorable outcome of cases with pre-existing liver disease. There have been speculations about risk factors for severe diseases such as liver disease, age, gender, and association with obesity or diabetes.

show abstract

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

Section: Covid-19 and Liver Chemistrymentioning

confidence: 99%

See 3 more Smart Citations

Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver

Săbiescu

Kamal

et al. 2022

JMedLife

View full text Add to dashboard Cite

show abstract

Meta-analysis of liver injury in patients with COVID-19

Fan

Jin

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) is a major public health problem threatening human health. It can lead to multiple system complications, among which liver damage is also a common complication of COVID-19. The pathogenesis of liver injury is complex and involves the interaction of multiple factors. This study aims to investigate the incidence and risk factors of liver injury in COVID-19 patients and analyze the impact of liver injury on clinical prognosis of patients, so as to provide corresponding basis for clinical diagnosis and treatment. Methods: PubMed and Cochrane Library were searched in computer to collect original studies on liver injury cases, laboratory indicators and clinical outcomes in COVID-19 patients. Articles were screened according to inclusion and exclusion criteria, and data were meta-analyzed using Stata12.0 software. Results: A total of 49 studies, including 23,611 patients with COVID-19, had a prevalence of liver injury of 39.63%. Subgroup analysis found that patients in the Americas had the highest incidence of liver injury at 43.7% and lowest in Africa (25.99%). The vast majority of liver injury is manifested by aminotransferase or bilirubin levels greater than 1 times the upper limit of normal (49.16%). The older the age, the male, the associated chronic liver disease, and the higher the levels of white blood cells, neutrophils, and C-reactive protein, the higher the risk of liver injury. The use of hormones, hydroxychloroquine, and tocilizumab increases the risk of liver injury. Patients with concurrent liver injury have longer hospital stays, are more likely to progress to severe cases, and have a higher risk of death than patients without liver injury. Conclusion: The incidence of liver injury in COVID-19 patients was high, affected by age, gender, chronic liver disease, inflammatory state and medication, and patients with liver injury were hospitalized longer and were more likely to have a poor prognosis. Therefore, clinical attention should be paid to early intervention.

show abstract

Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice

Pantazis

Pechlivanidou

Antoniadou

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Remdesivir was the first antiviral approved for COVID-19. We investigated its patterns of use, effectiveness and safety in clinical practice in Greece. Methods Retrospective observational study of hospitalized adults who received remdesivir for COVID-19 between 09/2020–02/2021. Main endpoints were time to recovery (hospital discharge within 30 days from admission) and safety. The “early” (remdesivir initiation within 2 days) and the “deferred” (remdesivir initiation > 2days after admission) groups were compared. Results 1004 patients (60.6% male, mean age 61 years, 74.3% with severe disease, 70.9% with ≥1 comorbidities) were included, 75.9% of them on a 5-days regimen and 86.8% in the early group. Among those with baseline mild/moderate disease, median (95% CI) time to recovery was 8 (7–9) and 12 (11–14) days for the early and deferred group respectively (p < 0.001). Corresponding estimates for those with severe disease: 10 (9–10) and 13 (11–15) days, respectively (p = 0.028). After remdesivir initiation, increased serum transaminases and acute kidney injury were observed in 6.9% and 2.1%, respectively. Nine (0.9%) patients discontinued treatment due to adverse events. Conclusions Effectiveness of remdesivir was higher when taken within the first 2-days of admission regardless of disease severity. Remdesivir safety profile was similar to that described in clinical trials and other real-world cohorts.

show abstract

Prevalence of abnormal liver biochemistry and its impact on COVID-19 patients’ outcomes: a single-center Greek study

Cited by 15 publications

References 21 publications

Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver

Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver

Meta-analysis of liver injury in patients with COVID-19

Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice

Contact Info

Product

Resources

About